NCT00763932View on ClinicalTrials.gov

Extension Study of Long-term Safety and Efficacy of Myozyme in Patients With Pompe Disease Who Were Previously Enrolled in Genzyme Sponsored Enzyme Replacement Therapy (ERT) Studies

PHASE2CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

April 30, 2003

Primary Completion Date

June 30, 2006

Study Completion Date

July 31, 2006

Conditions
Pompe Disease Infantile-OnsetGlycogen Storage Disease Type II
Interventions
BIOLOGICAL

Myozyme

10 mg/kg or 20 mg/kg qw OR 20 mg/kg or 40 mg/kg qow

Trial Locations (8)

Unknown

Children's Hospital of Oakland, Oakland

Children's Hospital of Orange Country, Orange

University of Nebraska Medical Center, Omaha

Institute for Genetic Medicine, Saint Peter's University Hospital, New Brunswick

New York University [NYU] School of Medicine, New York

Pediatrique Hospital Debrousse, Lyon

Hôpital Porte Madeleine, Orléans

The Morningside Clinic, Johannesburg

All Listed Sponsors
lead

Genzyme, a Sanofi Company

INDUSTRY

NCT00763932 - Extension Study of Long-term Safety and Efficacy of Myozyme in Patients With Pompe Disease Who Were Previously Enrolled in Genzyme Sponsored Enzyme Replacement Therapy (ERT) Studies | Biotech Hunter | Biotech Hunter